Paris, 17 May 2021
ENS@T-HT partners submitted a new patent application to develop a multi-omics signature and use of identified biomarkers to detect endocrine types of hypertension, different from primary hypertension.
The patent application coordinated by Inserm-Transfert was submitted in February 2021. The identified signature allows to stratify patients with arterial hypertension and to identify endocrine hypertension with a high specificity and sensitivity. The algorithm was developed on the omics data acquired and cleaned by the different co-inventor centers through machine learning approaches applied by the partners from the University of Dundee.
The signature was identified using clinical and omics data from a retrospective study of patients recruited by ENSAT-HT partner centers who are reference centres for endocrine forms of hypertension of adrenal origin (primary hyperaldosteronism, Cushing's syndrome and pheochromocytoma/functional paraganglioma).
At the moment, the current signature contains a large number of different types of omics. The broad clinical application of a diagnostic test requires that this signature be refined to a signature with fewer components. This signature must then be compared to the classical diagnostic process to assess its performance. For this purpose, a large prospective study was carried out within the consortium, which allowed the recruitment of approximately 2000 patients by 6 ENSAT-HT partner centres, who are also ESH Excellence centres. Omics analyses were performed for about 1000 patients by different partners.
In the coming months part of this data will be analysed to fine-tune the algorithm developed by ENSAT-HT, resulting in a final signature with a reduced number of components. The other part of the data from the prospective study will be used to compare the performance of the signature with conventional diagnostic methods.
In order to make a real difference in the management of hypertensive patients, a diagnostic test that can be easily used in the clinic must be developed to distinguish patients with endocrine forms of hypertension from patients with primary forms of hypertension at the outset.
To achieve this development and to bring this project to a successful conclusion, the ENSAT-HT consortium is seeking to collaborate with an industrial partner.
More detail about ENS@T-HT, a multiple-step-project with access to unique cohorts of patients in Europe
-- In an initial exploratory phase partners will establish omics-derived signatures of patients with PA, PPGL and CS through bioinformatics modelling of large datasets derived from multiple platforms.
-- The signatures will be validated as stratification biomarkers by establishing reference values and variability in healthy controls.
-- They will subsequently be used in a prospective clinical study to identify endocrine forms of hypertension and to stratify patients with arterial hypertension. The usefulness and cost-effectiveness of this approach will be evaluated in comparison to current standard of care outcomes and costs.
ENS@T-HT is based on the exploitation of unique cohorts of patients with PA, PPGL and CS recruited by reference centers for adrenal disorders organized within the European Network for the Study of Adrenal Tumors ENS@T (www.ensat.org). ENSAT-HT will take advantage of the prospective collaboration of six European Society of Hypertension ESH Centres of Excellence (http://www.eshonline.org) , providing a unique capability for the recruitment and workup of a large cohort of hypertensive patients.
Website : http://www.ensat-ht.eu
Maria-Christina Zennaro, Inserm Research Director Paris Cardiovascular Research Center
+33 (0)1 53 98 80 42